Search
Research
Romidepsin enhances the efficacy of cytarabine in vivo, revealing HDAC inhibition as a therapeutic strategy for KMT2A-rearranged acute lymphoblastic leukemiaIn this study, we investigate the in vivo synergy between romidepsin and cytarabine
Research
Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironmentOur results identify a pretreatment tumor microenvironment that predicts response to immune checkpoint blockade, which can be therapeutically attained
Research
Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemiaWe found two known risk factors in a large cohort of children treated for ALL and identified other factors associated with venous thromboembolism
Research
Acquired resistance during adoptive cell therapy by transcriptional silencing of immunogenic antigensThese findings suggest that tumor cells employ multiple epigenetic and genetic mechanisms to evade immune control
Research
The Australian and New Zealand Children's Haematology/Oncology Group Biobanking NetworkThe ANZCHOG-BN is a new biobank network in Australasia that was developed to improve and streamline access to high-quality pediatric and AYA cancer biospecimens
Research
Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized StudyEarly intensification with postinduction myeloid-type chemotherapy courses did not significantly improve outcome for infant acute lymphoblastic leukemia
Research
Challenges posed by COVID-19 to children with cancerDevelopment of standardised guidance by national and regional authorities for reducing the risk of SARS-CoV-2 transmission to children with cancer
News & Events
Delivering smart drugs into cellsThe Drug Discovery Unit has been finding ways for smart drugs to penetrate deep into cells and attacking their disease targets while causing fewer side effects
News & Events
New test proves effective in more cancersAvantogen Limited (ACU:ASX) today announced that cancer researchers at Perth's The Kids for Child Health Research (TICHR) and Avantogen Limited